Atossa Therapeutics Appoints New Chief Financial Officer

Atossa Therapeutics ( (ATOS) ) has shared an update.

On October 14, 2025, Atossa Therapeutics announced the appointment of Mark Daniel as Chief Financial Officer, succeeding Heather Rees. Daniel’s extensive experience in finance and capital markets is expected to support Atossa’s transition from clinical development to commercialization, particularly for its (Z)-endoxifen product. His expertise in revenue forecasting, financial discipline, and capital strategy is anticipated to enhance Atossa’s operational readiness and market entry strategy.

The most recent analyst rating on (ATOS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.

Spark’s Take on ATOS Stock

According to Spark, TipRanks’ AI Analyst, ATOS is a Underperform.

Atossa Therapeutics’ stock score is weighed down by significant financial challenges, including ongoing operational losses and negative cash flow, despite a debt-free balance sheet. Technical indicators suggest short-term overbought conditions, while the valuation remains unattractive due to a lack of profitability and dividends. Although the earnings call provided some positive guidance on cost reductions and clinical progress, these are overshadowed by the company’s financial instability.

To see Spark’s full report on ATOS stock, click here.

More about Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet needs in breast cancer treatment and prevention. The company emphasizes disciplined capital allocation and focuses resources on programs that can enable future regulatory submissions and potential commercialization.

Average Trading Volume: 1,028,483

Technical Sentiment Signal: Hold

Current Market Cap: $139.5M

For a thorough assessment of ATOS stock, go to TipRanks’ Stock Analysis page.